David Spencer - Bellicum Pharmaceuticals Insider

BLCM -- USA Stock  

USD 6.12  0.14  2.24%

Dr. David M. Spencer, Ph.D. is Chief Technology Officer of the Company
Age: 54  Founder Since 2018  Ph.D    
832-384-1100  http://www.bellicum.com
Spencer cofounded Bellicum in July 2004 and served as a member of our Board until September 2004. He has served as a scientific advisor to the Company since our inception. From January 1996 to November 2011, Dr. Spencer served as professor in the department of Pathology and Immunology at Baylor College of Medicine and as Vice Chairman of the department from January 2010 to November 2011. He graduated magna cum laude with a B.A. in Chemistry from the University of California, San Diego and received his Ph.D. in Biology at Massachusetts Institute of Technology and was a postdoctoral fellow at Stanford University.

David Spencer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (33.25) % which means that it has lost $33.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (78.53) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 35.53 M in liabilities with Debt to Equity (D/E) ratio of 31.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bellicum Pharmaceuticals has Current Ratio of 10.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. Bellicum Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 137 people.Bellicum Pharmaceuticals (BLCM) is traded on BATS Exchange in USA. It is located in TEXAS U.S.A and employs 137 people. Bellicum Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Bellicum Pharmaceuticals Leadership Team

Frank McGuyer, Director
Richard Fair, President CEO, Director
Stephen Davis, Independent Director
Reid Huber, Director
Peter Hoang, Senior Vice President - Business Development and Strategy
Alan Musso, CFO, Treasurer
Kevin Slawin, Chief Medical Officer, CTO, Director
David Spencer, Co-Founder and Chief Scientific Officer
Jon Stonehouse, Director
James Brown, Chairman of the Board
Edmund Harrigan, Director
Jim Daly, Director
Rosemary Williams, Interim Principal Accounting Officer
Ken Moseley, Vice President - Intellectual Property and Legal Affairs
Annemarie Moseley, COO, Senior Vice President - Clinical Development and Regulatory Affairs
James Daly, Director
Shane Ward, General Counsel and Corporate Secretary
Alan Smith, Executive Vice President of Technical Operations
Dennis Stone, Director
Thomas Farrell, CEO and President and Director
Gregory Naeve, Chief Business Officer
William Grossman, Chief Medical Officer
Joseph Senesac, Vice President - Manufacturing

Stock Performance Indicators

Did you try this?

Run Commodity Channel Index Now


Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Commodity Channel Index

Bellicum Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bellicum Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Search macroaxis.com